πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron UK Patents

Full USPTO pharma patent portfolio for Regeneron UK β€” grant dates, expiration, and drug cross-links.

Patents
837
Expiring ≀24m
26

Quick answer

Regeneron UK has 837 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 26 expire within 24 months β€” use filters for patent-cliff planning.

Page 14 of 18

  1. US 9358287

    Method of treating stress hyperglycemia with human antibodies to the glucagon receptor

    Expires Mon Jun 02 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9353176

    Method of treating osteoarthritis with an antibody to NGF

    Expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9353163

    Apelin fusion proteins and uses thereof

    Expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9340594

    VEGF antagonist formulations for intravitreal administration

    Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9308256

    Method of treating rheumatoid arthritis with an anti-IL-6R antibody

    Expires Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9309326

    Readily isolated bispecific antibodies with native immunoglobulin format

    Expires Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9301509

    Genetically modified mice and engraftment

    Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9302015

    Anti-PRLR antibodies and methods for killing PRLR-expressing cells

    Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9290574

    Methods for treating eosinophilic esophagitis by administering an IL-4R inhibitor

    Expires Mon Mar 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9284380

    Anti-ErbB3 antibodies and uses thereof

    Expires Mon Mar 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9273143

    Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody

    Expires Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9265827

    Anti-PDGFR-beta antibodies and uses thereof

    Expires Mon Feb 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9260515

    Antibodies to human GDF8

    Expires Mon Feb 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9254338

    Use of a VEGF antagonist to treat angiogenic eye disorders

    Expires Mon Feb 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9238692

    Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

    Expires Mon Jan 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9228014

    Antibodies capable of blocking the interaction between CD48 and a CD48 receptor

    Expires Mon Dec 31 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9193977

    Non-human animals having a humanized signal-regulatory protein gene

    Expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9193801

    Stabilized formulations containing anti-PCSK9 antibodies

    Expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9173880

    Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9150648

    Anti-ASIC1 antibodies and uses thereof

    Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9139644

    Modified chimeric polypeptides with improved pharmacokinetic properties

    Expires Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9132192

    Anti-EGFR antibodies and uses thereof

    Expires Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9127292

    Non-human animals having a humanized signal-regulatory protein gene

    Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9127068

    Nucleic acids encoding human glucagon receptor antibodies

    Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9120851

    Human antibodies to human angiopoietin-like protein 4

    Expires Mon Aug 27 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9089599

    Low affinity FCGR deficient mice

    Expires Mon Jul 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9079948

    Human antibodies to Fel d1 and methods of use thereof

    Expires Mon Jul 09 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9056130

    Humanized Fc gamma R mice

    Expires Mon Jun 11 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9043996

    Genetically modified major histocompatibility complex animals

    Expires Mon May 28 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9028819

    Methods of alleviating itch by administering human antibodies to human protease-activated receptor 2

    Expires Mon May 07 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9018356

    Anti-ANGPTL3 antibodies and uses thereof

    Expires Mon Apr 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9017670

    Anti-Tie2 antibodies and uses thereof

    Expires Mon Apr 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9005617

    Antikine antibodies that bind to multiple CC chemokines

    Expires Mon Apr 09 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8987420

    High affinity human antibodies to human angiopoietin-2

    Expires Mon Mar 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8980268

    Methods for treating cancer by administering an anti-Ang-2 antibody

    Expires Mon Mar 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8968736

    Human antibodies to GFRΞ±3 and methods of use thereof

    Expires Mon Feb 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8945559

    Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

    Expires Mon Jan 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8927233

    Fusion polypeptides capable of activating receptors

    Expires Mon Jan 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8921316

    Stable liquid VEGF antagonist formulations

    Expires Mon Dec 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8889133

    Methods of treating diabetes with Dll4 antagonists

    Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8871209

    Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or Activin A

    Expires Mon Oct 23 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8865430

    Fusion polypeptides capable of activating receptors

    Expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8847004

    Humanized M-CSF mice

    Expires Mon Sep 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8840894

    Antibodies to human GDF8

    Expires Mon Sep 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8840886

    Method of treating cancer with DLL4 antagonist and chemotherapeutic agent

    Expires Mon Sep 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8802107

    VEGF antagonist formulations for intravitreal administration

    Expires Mon Aug 07 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8795669

    Stabilized formulations containing anti-PCSK9 antibodies

    Expires Mon Jul 31 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8791244

    Anti-ErbB3 antibodies and uses thereof

    Expires Mon Jul 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron UK have?

837 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron UK patents expire?

26 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.